Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saroglitazar magnesium versus placebo in primary biliary cholangitis
2022-001634-10Phase 2Terminated
- Sponsor
- Zydus Therapeutics
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of saroglitazar magnesium in primary biliary cholangitis (PBC) (3 arms), sponsored by Zydus Therapeutics. Primary endpoint: Biochemical response at Week 52. Started Oct 2022; status: terminated.
02
Drugs
saroglitazar magnesium
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on 2022-001634-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001634-10.